biostudies-literatureUnknown105Beyene HB<h4>Background</h4>Decreased levels of circulating ethanolamine plasmalogens [PE(P)], and a concurrent increase in phosphatidylethanolamine (PE) are consistently reported in various cardiometabolic conditions. Here we devised, a plasmalogen score (Pls Score) that mirrors a metabolic signal that encompasses the levels of PE(P) and PE and captures the natural variation in circulating plasmalogens and perturbations in their metabolism associated with disease, diet, and lifestyle.<h4>Methods</h4>We utilised, plasma lipidomes from the Australian Obesity, Diabetes and Lifestyle study (AusDiab; n = 10,339, 55% women) a nationwide cohort, to devise the Pls Score and validated this in the Busselton Health Study (BHS; n = 4,492, 56% women, serum lipidome) and in a placebo-controlled crossover trial EBioMedicine105187https://www.ebi.ac.uk/biostudies/studies/S-EPMC11215217biostudies-literatureDevelopment and validation of a plasmalogen score as an independent modifiable marker of metabolic health: population based observational studies and a placebo-controlled cross-over study.PMC11215217Moses EKBlangero JPaul SHui JMellett NAMagliano DJMeikle TGHung JGiles CHuynh KOlshansky GMeikle PJBeyene HBWang TCinel MBeilby JWatts GFShaw JEfalseDevelopment and validation of a plasmalogen score as an independent modifiable marker of metabolic health: population based observational studies and a placebo-controlled cross-over study.<h4>Background</h4>Decreased levels of circulating ethanolamine plasmalogens [PE(P)], and a concurrent increase in phosphatidylethanolamine (PE) are consistently reported in various cardiometabolic conditions. Here we devised, a plasmalogen score (Pls Score) that mirrors a metabolic signal that encompasses the levels of PE(P) and PE and captures the natural variation in circulating plasmalogens and perturbations in their metabolism associated with disease, diet, and lifestyle.<h4>Methods</h4>We utilised, plasma lipidomes from the Australian Obesity, Diabetes and Lifestyle study (AusDiab; n = 10,339, 55% women) a nationwide cohort, to devise the Pls Score and validated this in the Busselton Health Study (BHS; n = 4,492, 56% women, serum lipidome) and in a placebo-controlled crossover trial 2024-01-01T00:00:00Z2024 Jun2025-04-18T15:27:16.277Z2025-04-07T02:07:33.146ZS-EPMC112152173886187010.1016/j.ebiom.2024.105187